Tune Therapeutics CEO John McHutchison, MD, delves into the clinical data for TUNE-401, a groundbreaking drug that effectively silences both episomal and integrated hepatitis B virus DNA. The post Phase Ib/IIa for Hepatitis B Epigenetic Silencer Shows Best-in-Class Potential appeared first on Inside Precision Medicine .